Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-5 canceled.

6. (Withdrawn) Use of a substance according to claim 4 wherein the proteasome inhibitor is selected from a group comprising:

a) epoxomicin ($C_{28}H_{86}N_4O_7$) and/or

b) eponemycin ($C_{20}H_{36}N_2O_5$).

7. (Withdrawn) Use of substance according to claim 4, wherein the proteasome inhibitor is selected from a group comprising:

a) PS-314 as a peptidyl-boric-acid derivative which is N-pyrazinecarbonyl-L-phenylalanin-L-leuzin- boric acid ($C_{19}H_{25}BN_4O_4$);

b) PS-519 as a β-lacton- and a lactacystin-derivative which is 1R-[1S, 4R, 5S] -1-(1-Hydroxy-2methylpropyl)-4-propyl-6-oxa-2azabicyclo[3.2.0]heptane-3,7-dione ($C_{12}H_{19}NO_4$);

c) PS-273 (morpholin-CONH-(CH-naphthyl)-CONH-(CH-isobutyl)-$B(OH)_2$) and its enantiomere;

d) PS-293;

e) PS-296 (8-quinolyl-sulfonyl-CONH-(CH-napthyl)-CONH(-CH-isobutyl)-$B(OH)_2$);

f) PS-303 (NH_2(CH-naphthyl)-CONH-(CH-isobutyl)-$B(OH)_2$;

g) PS-321 as (morpholin-CONH-(CH-napthyl)-CONH-(CH-phenylalanin)-$B(OH)_2$);

h) PS-334 (CH_3-NH-(CH-naphthyl-CONH-(CH-Isobutyl)-$B(OH)_2$);

i) PS-325 (2-quinol-CONH-(CH-homo-phenylalanin)-CONH-(CH-isobutyl)- $B(OH)_2$;

j) PS-352 (phenyalanin-CH_2-CH_2-CONH-(CH-isobutyl)I-$B(OH)_2$;

k) PS-383 (pyridyl-CONH-(CH_pF-phenylalanin)-CONH-(CH-isobutyl)-$B(OH)_2$);

l) PS-341; and

m) PS-1 Z-Ile-Glu(O*t*Bu)-Ala-Leu-CHO;

PS-2 [Benzyloxycarbonyl)-Leu-Leu-phenylalaninal or Z-LLF-CHO or Z-Leu-Leu-Phe-CHO PS-1.

8. (Withdrawn) Use of a substance according to claim 7, wherein the substance is selected from the group comprising:

a) PS-341 and

b) PS-1 Z-Ile-Glu(O*t*Bu)-Ala-Leu-CHO;

PS-2 [Benzyloxycarbonyl)-Leu-Leu-phenylalaninal or Z-LLF-CHO or Z-Leu-Leu-Phe-CHO PS-1.

c) PS-519 as a β-lacton- and a lactacystin-derivative which is 1R-[1S, 4R, 5S]-1-(1-Hydroxy-2methylpropyl)-4-propyl-6-oxa-2azabicyclo[3.2.0]heptane-3,7-dione ($C_{12}H_{19}NO_4$)

9. (Previously Presented) A method for treating a patient infected with a virus selected from the group consisting of varicella zoster virus, human cytomegalovirus, HHV6 and 7, Epstein-Barr virus and HHV8, comprising administering one or more proteasome inhibitors to said patient.

10. (Previously Presented) The method according to claim 9 wherein said patient is a human and said virus is human cytomegalovirus.

11. (Previously Presented) The method according to claim 9, wherein said patient has undergone organ transplantation, is receiving immuno-suppressing chemotherapy, is otherwise immuno-suppressed, has a septic disease or has AIDS.

12. (Previously Presented) The method according to claim 9, wherein said proteasome inhibitor is selected from a group consisting of substances which are able to block the enzymatic activity of the 26S proteasome complex and/or block enzymatic activity of the 20S proteasome core structure.

13. (Previously Presented) The method according to claim 9, wherein said proteasome inhibitor is selected from the group consisting of:

a) naturally occurring proteasome inhibitors,

b) synthetic proteasome inhibitors,

c) peptides,

d) Glyoxal- or boric acid residues, and

e) Pinacol-esters.

14. (Previously Presented) The method according to claim 13, wherein said naturally occurring proteasome inhibitors are selected from the group consisting of peptide derivatives which have a C-terminal expoxy keton structure, β-lacton-derivatives, aclacinomycin A, lactacystin, and clastolactacystein.

15. (Previously Presented) The method according to claim 13, wherein said synthetic proteasome inhibitors are selected from the group consisting of modified peptide aldehydes, a boric acid derivative of MG232, N-carbobenzoxy-Leu-Nva-H (also referred to as MG115), N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal (also referred to as LLnL), and N-carbobenzoxy-Ile-Glu(OBut)-Ala-Leu-H (also referred to as PS-1).

16. (Previously Presented) The method according to claim 15, wherein said modified peptide aldehyde is N-carbobenzoxy-L-leucinyl-L-leucinyl-L-leucinal (also referred to as MG132 or zLLL).

17. (Previously Presented) The method according to claim 13, wherein said peptides are selected from the group consisting of an α, β,-epoxyketone-structure and vinyl-sulfones.

18. (Previously Presented) The method according to claim 17, wherein said vinyl-sulfones are selected from the group consisting of carbobenzoxy-L-leucinyl-L-leucinyl-L-leucin-vinyl-sulfon and 4-hydroxy-5-iodo-3-nitrophenylacetyl-L-leucinyl-L-leucinyl-L-leucin-vinyl-sulfon (NLVS).

19. (Previously Presented) The method according to claim 13, wherein said Glyoxal- or boric acid residues are selected from the group consisting of pyrazyl-CONH(CHPhe)CONH(CHisobutyl)$B(OH)_2$ and dipeptidyl-boric-acid derivatives.

20. (Previously Presented) The method according to claim 13, wherein said Pinacol-ester is benzyloxycarbonyl(Cbz)-Leu-leuboro-Leu-pinacol-ester.

21. (New) A method for preparing and administering a medicament for treating a patient infected with a virus selected from the group consisting of varicella zoster virus, human cytomegalovirus, HHV6 and 7, Epstein-Barr virus and HHV8, comprising combining one or more proteasome inhibitors with a pharmaceutically acceptable carrier to produce a medicament and administering said medicament to said patient infected with a virus selected from the group consisting of varicella zoster virus, human cytomegalovirus, HHV6 and 7, Epstein-Barr virus and HHV8.

22. (New) The method according to claim 21, wherein said patient is a human and said virus is human cytomegalovirus.

23. (New) The method according to claim 21, wherein said patient has undergone organ transplantation, is receiving immuno-suppressing chemotherapy, is otherwise immuno-suppressed, has a septic disease or has AIDS.

24. (New) The method according to claim 21, wherein said proteasome inhibitor is selected from a group consisting of substances which are able to block the enzymatic activity of the 26S proteasome complex and/or block enzymatic activity of the 20S proteasome core structure.

25. (New) The method according to claim 21, wherein said proteasome inhibitor is selected from the group consisting of:

a) naturally occurring proteasome inhibitors,

b) synthetic proteasome inhibitors,

c) peptides,

d) Glyoxal- or boric acid residues, and

e) Pinacol-esters.

26. (New) The method according to claim 25, wherein said naturally occurring proteasome inhibitors are selected from the group consisting of peptide derivatives which have a C-terminal expoxy keton structure, β-lacton-derivatives, aclacinomycin A, lactacystin, and clastolactacystein.

27. (New) The method according to claim 25, wherein said synthetic proteasome inhibitors are selected from the group consisting of modified peptide aldehydes, a boric acid derivative of MG232, N-carbobenzoxy-Leu-Nva-H (also referred to as MG115), N-acetyl-L-leucinyl-L-leucinyl-L-norleucinal (also referred to as LLnL), and N-carbobenzoxy-Ile-Glu(OBut)-Ala-Leu-H (also referred to as PS-1).

28. (New) The method according to claim 27, wherein said modified peptide aldehyde is N-carbobenzoxy-L-leucinyl-L-leucinyl-L-leucinal (also referred to as MG132 or zLLL).

29. (New) The method according to claim 25, wherein said peptides are selected from the group consisting of an α, β,-epoxyketone-structure and vinyl-sulfones.

30. (New) The method according to claim 29, wherein said vinyl-sulfones are selected from the group consisting of carbobenzoxy-L-leucinyl-L-leucinyl-L-leucin-vinyl-sulfon and 4-hydroxy-5-iodo-3-nitrophenylacetyl-L-leucinyl-L-leucinyl-L-leucin-vinyl-sulfon (NLVS).

31. (New) The method according to claim 25, wherein said Glyoxal- or boric acid residues are selected from the group consisting of pyrazyl-CONH(CHPhe)CONH(CHisobutyl)$B(OH)_2$ and dipeptidyl-boric-acid derivatives.

32. (New) The method according to claim 25, wherein said Pinacol-ester is benzyloxycarbonyl(Cbz)-Leu-leuboro-Leu-pinacol-ester.